

Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study

NCT07301216

Status RECRUITING
Sponsor Yale University
Enrollment 30 participants

Key Eligibility Criteria

Inclusion (8)

- Patients with Wilson Disease as defined by Leipzig score e4.
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures (serial 24 h urine collections and local collection of samples for NCC, liver function and estimated GFR) and availability for the duration of the study.
- Treated WD for at least 12 months prior to study entry.
- Aminotransferase values (ASAT and ALAT) \lt 2 times the upper limit of normal (ULN).

... and 3 more (see full listing online)

Exclusion (7)

- Current dual / mixed therapy for WD (i.e. zinc and d-penicillamine or trientine at the same time)
- Current Pregnancy or lactation. *
- Recent estrogen-based treatment (in the last month).
- Cirrhosis with recent hepatic decompensation (within the last 6 months) - new onset of ascites, spontaneous bacterial peritonitis, esophageal variceal bleeding, or hepatic encephalopathy
- Investigator believes the patient will be unable to do the required 24-hour urine studies and participate in the follow up visits as expected.

... and 2 more (see full listing online)

Locations (1 total)

Yale School of Medicine, New Haven, Connecticut, United States